Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.

Rothen, Dominik A; Krenger, Pascal S; Nonic, Aleksandra; Balke, Ina; Vogt, Anne-Cathrine S; Chang, Xinyue; Manenti, Alessandro; Vedovi, Fabio; Resevica, Gunta; Walton, Senta M; Zeltins, Andris; Montomoli, Emanuele; Vogel, Monique; Bachmann, Martin F; Mohsen, Mona O (2022). Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern. Allergy, 77(8), pp. 2446-2458. Wiley 10.1111/all.15311

[img]
Preview
Text
Allergy_-_2022_-_Rothen_-_Intranasal_administration_of_a_VLP_based_vaccine_induces_neutralizing_antibodies_against.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (14MB) | Preview

BACKGROUND

The highly contagious SARS-CoV-2 is mainly transmitted by respiratory droplets and aerosols. Consequently, people are required to wear masks and maintain a social distance to avoid spreading of the virus. Despite the success of the commercially available vaccines, the virus is still uncontained globally. Given the tropism of SARS-CoV-2, a mucosal immune reaction would help to reduce viral shedding and transmission locally. Only seven out of hundreds of ongoing clinical trials are testing the intranasal delivery of a vaccine against COVID-19.

METHODS

In the current study, we evaluated the immunogenicity of a traditional vaccine platform based on virus-like particles (VLPs) displaying RBD of SARS-CoV-2 for intranasal administration in a murine model. The candidate vaccine platform, CuMVTT -RBD, has been optimized to incorporate a universal T helper cell epitope derived from tetanus-toxin and is self-adjuvanted with TLR7/8 ligands.

RESULTS

CuMVTT -RBD vaccine elicited a strong systemic RBD- and spike- IgG and IgA antibodies of high avidity. Local immune response was assessed and our results demonstrate a strong mucosal antibody and plasma cell production in lung tissue. Furthermore, the induced systemic antibodies could efficiently recognize and neutralize different variants of concern (VOCs) of mutated SARS-CoV-2 RBDs.

CONCLUSION

Our data demonstrate that intranasal administration of CuMVTT -RBD induces a protective systemic and local specific antibody response against SARS-CoV-2 and its VOCs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Rothen, Dominik Alexander, Krenger, Pascal Siegfried, Nonic, Aleksandra, Vogt, Anne-Cathrine Sarah, Chang, Xinyue, Vogel, Monique, Bachmann, Martin (B), Mohsen, Mona Omar Mahmoud

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1398-9995

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

12 Apr 2022 10:14

Last Modified:

13 Apr 2023 00:25

Publisher DOI:

10.1111/all.15311

PubMed ID:

35403221

Uncontrolled Keywords:

COVID-19 SARS-CoV-2 intranasal vaccine virus-like particles

BORIS DOI:

10.48350/169225

URI:

https://boris.unibe.ch/id/eprint/169225

Actions (login required)

Edit item Edit item
Provide Feedback